293 related articles for article (PubMed ID: 32020844)
1. Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors.
Tomita T
Bosn J Basic Med Sci; 2020 Aug; 20(3):336-346. PubMed ID: 32020844
[TBL] [Abstract][Full Text] [Related]
2. Significance of chromogranin A and synaptophysin in medullary thyroid carcinoma.
Tomita T
Bosn J Basic Med Sci; 2021 Oct; 21(5):535-541. PubMed ID: 33485291
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
4. Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears.
Hou T; Gan Q; Joseph CT; Sun X; Gong Y
Cancer Cytopathol; 2020 Oct; 128(10):725-732. PubMed ID: 32573984
[TBL] [Abstract][Full Text] [Related]
5. PGP 9.5 immunocytochemical staining for pancreatic endocrine tumors.
Tomita T
Islets; 2013; 5(3):122-8. PubMed ID: 23959334
[TBL] [Abstract][Full Text] [Related]
6. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
[TBL] [Abstract][Full Text] [Related]
8. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
[TBL] [Abstract][Full Text] [Related]
10. [Gastrointestinal and pancreatic neuroendocrine tumors: a clinicopathologic and immunohistochemical study].
Sun LM; Qiu XS; Wang EH
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):696-7. PubMed ID: 23302313
[No Abstract] [Full Text] [Related]
11. Chromogranin A: its clinical value as marker of neuroendocrine tumours.
Nobels FR; Kwekkeboom DJ; Bouillon R; Lamberts SW
Eur J Clin Invest; 1998 Jun; 28(6):431-40. PubMed ID: 9693933
[TBL] [Abstract][Full Text] [Related]
12. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
13. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
14. Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience.
Rodriguez EF; Fite JJ; Chowsilpa S; Maleki Z
Hum Pathol; 2019 Mar; 85():128-135. PubMed ID: 30502379
[TBL] [Abstract][Full Text] [Related]
15. Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors.
Möller K; Uhlig R; Gorbokon N; Dum D; Menz A; Büscheck F; Luebke AM; Hube-Magg C; Hinsch A; Höflmayer D; Fraune C; Lebok P; Weidemann S; Lennartz M; Jacobsen F; Clauditz TS; Steurer S; Burandt E; Krech R; Krech T; Marx AH; Sauter G; Simon R; Bernreuther C; Minner S
Mol Cell Endocrinol; 2024 Feb; 581():112106. PubMed ID: 37951531
[TBL] [Abstract][Full Text] [Related]
16. Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET).
Andreasi V; Partelli S; Manzoni M; Muffatti F; Colombo B; Corti A; Falconi M
Pancreatology; 2019 Jan; 19(1):57-63. PubMed ID: 30470614
[TBL] [Abstract][Full Text] [Related]
17. A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms.
Liu B; Kudo A; Kinowaki Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Akashi T; Tanabe M
J Gastroenterol; 2019 Sep; 54(9):819-828. PubMed ID: 30863885
[TBL] [Abstract][Full Text] [Related]
18. [Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].
Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):257-62. PubMed ID: 21616002
[No Abstract] [Full Text] [Related]
19. Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A.
Lai M; Lü B; Xing X; Xu E; Ren G; Huang Q
Virchows Arch; 2006 Oct; 449(4):402-9. PubMed ID: 16955307
[TBL] [Abstract][Full Text] [Related]
20. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]